ダウンロード数: 175
このアイテムのファイル:
ファイル | 記述 | サイズ | フォーマット | |
---|---|---|---|---|
j.rmcr.2015.05.003.pdf | 1.3 MB | Adobe PDF | 見る/開く |
タイトル: | Successful treatment with carboplatin and nanoparticle albumin-bound paclitaxel in a patient with pulmonary spindlecellcarcinoma |
著者: | Tsuji, Takahiro Kim, Young Hak Ozasa, Hiroaki Sakamori, Yuichi https://orcid.org/0000-0001-6421-7266 (unconfirmed) Nagai, Hiroki Ajimizu, Hitomi Yagi, Yoshitaka Furukawa, Atsuyuki Haga, Hironori Mishima, Michiaki |
著者名の別形: | 金, 永学 小笹, 裕見 阪森, 優一 羽賀, 博典 三嶋, 理晃 |
キーワード: | Pulmonary sarcomatoid carcinoma Spindle cell carcinoma Nab-PTX |
発行日: | 1-May-2015 |
出版者: | Elsevier Ltd. |
誌名: | Respiratory Medicine Case Reports |
巻: | 15 |
開始ページ: | 48 |
終了ページ: | 50 |
抄録: | Introduction: Pulmonary spindle cell carcinoma (SpCC) is a rare subtype of non-small-cell lung cancer (NSCLC) and, in general, is chemoresistance. Case: A sixty-five year-old male patient with metastatic pulmonary SpCC was initially treated with cisplatin and docetaxel, but his disease progressed. Then, he received a combination chemotherapy with carboplatin and nab-PTX followed by maintenanced chemotherapy with nab-PTX. Fluorodeoxyglucose (FDG) positron-emission CT revealed a substantial decrease of FDG accumulation in the primary tumor, and the response continued for more than 7 months. Discussion: Preclinical models suggested that nab-PTX may reach the tumor microenvironment more efficiently than solvent-based paclitaxel (sb-PTX) and be preferentially taken up by cancer cells. Considering that there is no effective treatment for patients with pulmonary SpCC, nab-PTX may merit further investigation in patients with pulmonary SpCC. |
著作権等: | © 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license(http://creativecommons.org/licenses/by-nc-nd/4.0/). |
URI: | http://hdl.handle.net/2433/215118 |
DOI(出版社版): | 10.1016/j.rmcr.2015.05.003 |
PubMed ID: | 26236601 |
出現コレクション: | 学術雑誌掲載論文等 |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。